Exact Sciences Corporation (EXAS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Exact Sciences Corporatio... (EXAS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

54.26

-4.25 (-7.26%)

At close: Jan 14, 2025, 3:59 PM

54.56

0.55%

After-hours Jan 14, 2025, 07:59 PM EST

undefined% (undefined)

Bid	54.04
Market Cap	10.04B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.2
PE Ratio (ttm)	-45.22
Forward PE	n/a
Analyst	Buy

Ask	56.6
Volume	3,315,564
Avg. Volume (20D)	2,431,134
Open	58.89
Previous Close	58.51
Day's Range	53.39 - 59.94
52-Week Range	40.62 - 79.62
Beta	undefined

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Feb 1, 2001

Employees 6,500

Stock Exchange NASDAQ

Ticker Symbol EXAS

Website https://www.exactsciences.com

Analyst Forecast

According to 17 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $72, which is an increase of 32.69% from the latest price.

Buy 88.24%

Hold 5.88%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Exact Sciences Corporation is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $776.55M, reflecting a 20.04% YoY growth and earnings per share of -0.07, making a -74.07% decrease YoY.

Why Price Moved

1 month ago · Source

+9%

Exact Sciences shares are trading higher. The comp... Unlock content with Pro Subscription

2 months ago · Source

-23.48%

Exact Sciences shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

News

1 day ago · benzinga.com

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.

3 days ago · businesswire.com

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 mil...

1 week ago · zacks.com

Should Exact Sciences Stock Stay in Your Portfolio Right Now?

EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.

1 week ago · businesswire.com

Exact Sciences to Participate in J.P. Morgan Healthcare Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

1 month ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call P...

1 month ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)

Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Confere...

1 month ago · businesswire.com

Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Lo...

1 month ago · benzinga.com

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.

1 month ago · benzinga.com

Why Is Exact Sciences Stock Trading Higher On Monday?

On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.

1 month ago · businesswire.com

Exact Sciences to Participate in December Investor Conferences

1 month ago · businesswire.com

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision O...

1 month ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)

Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Offic...

1 month ago · zacks.com

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test

Exact Sciences presents new positive evidence backing the development of an MCED test.

2 months ago · businesswire.com

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in ...

2 months ago · seekingalpha.com

Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.

This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for ...

2 months ago · investopedia.com

Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount

Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.

2 months ago · benzinga.com

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.

2 months ago · zacks.com

Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.

2 months ago · benzinga.com

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.

2 months ago · seekingalpha.com

Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript

Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CE...

Load More News